Jane Street’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,202,531
| Closed | -$5.41M | – | 12582 |
|
|
2026
Q1 | $5.41M | Buy |
1,202,531
+1,148,114
| +2,110% | +$5.98M | ﹤0.01% | 3391 |
|
|
2025
Q4 | $335K | Sell |
54,417
-169,609
| -76% | -$1.23M | ﹤0.01% | 8591 |
|
|
2025
Q3 | $1.62M | Buy |
+224,026
| New | +$1.33M | ﹤0.01% | 5329 |
|
|
2025
Q2 | – | Sell |
-213,826
| Closed | -$1.9M | – | 10441 |
|
|
2025
Q1 | $1.9M | Buy |
213,826
+195,658
| +1,077% | +$2.35M | ﹤0.01% | 4441 |
|
|
2024
Q4 | $249K | Sell |
18,168
-103,013
| -85% | -$1.9M | ﹤0.01% | 8046 |
|
|
2024
Q3 | $3.32M | Buy |
121,181
+19,684
| +19% | +$533K | ﹤0.01% | 3534 |
|
|
2024
Q2 | $2.48M | Buy |
101,497
+66,711
| +192% | +$1.46M | ﹤0.01% | 4138 |
|
|
2024
Q1 | $742K | Sell |
34,786
-28,020
| -45% | -$602K | ﹤0.01% | 5972 |
|
|
2023
Q4 | $1.2M | Buy |
62,806
+21,248
| +51% | +$368K | ﹤0.01% | 5232 |
|
|
2023
Q3 | $667K | Sell |
41,558
-62,333
| -60% | -$1.19M | ﹤0.01% | 5806 |
|
|
2023
Q2 | $2.41M | Buy |
103,891
+36,372
| +54% | +$794K | ﹤0.01% | 3881 |
|
|
2023
Q1 | $1.57M | Buy |
67,519
+37,745
| +127% | +$767K | ﹤0.01% | 4228 |
|
|
2022
Q4 | $432K | Buy |
29,774
+9,207
| +45% | +$172K | ﹤0.01% | 6386 |
|
|
2022
Q3 | $392K | Buy |
+20,567
| New | +$472K | ﹤0.01% | 7139 |
|
|
2022
Q2 | – | Sell |
-33,814
| Closed | -$702K | – | 10449 |
|
|
2022
Q1 | $852K | Buy |
33,814
+12,712
| +60% | +$325K | ﹤0.01% | 6454 |
|
|
2021
Q4 | $583K | Buy |
+21,102
| New | +$611K | ﹤0.01% | 6974 |
|
|
2021
Q3 | – | Sell |
-21,200
| Closed | -$704K | – | 10440 |
|
|
2021
Q2 | $648K | Buy |
21,200
+8,234
| +64% | +$238K | ﹤0.01% | 6756 |
|
|
2021
Q1 | $395K | Sell |
12,966
-37,818
| -74% | -$1.07M | ﹤0.01% | 7230 |
|
|
2020
Q4 | $1M | Sell |
50,784
-2,570
| -5% | -$41.5K | ﹤0.01% | 4646 |
|
|
2020
Q3 | $696K | Buy |
53,354
+11,759
| +28% | +$149K | ﹤0.01% | 4658 |
|
|
2020
Q2 | $471K | Buy |
+41,595
| New | +$591K | ﹤0.01% | 5168 |
|
|
2020
Q1 | – | Sell |
-21,429
| Closed | -$584K | – | 5747 |
|
|
2019
Q4 | $584K | Buy |
21,429
+9,619
| +81% | +$265K | ﹤0.01% | 3502 |
|
|
2019
Q3 | $338K | Buy |
+11,810
| New | +$344K | ﹤0.01% | 4029 |
|
|
2018
Q2 | – | Sell |
-10,364
| Closed | -$306K | – | 5384 |
|
|
2018
Q1 | $306K | Buy |
+10,364
| New | +$351K | ﹤0.01% | 3999 |
|
|
2017
Q3 | – | Sell |
-14,458
| Closed | -$374K | – | 4861 |
|
|
2017
Q2 | $374K | Buy |
+14,458
| New | +$307K | ﹤0.01% | 3368 |
|
|
2016
Q4 | – | Sell |
-14,029
| Closed | -$289K | – | 4412 |
|
|
2016
Q3 | $289K | Buy |
+14,029
| New | +$356K | ﹤0.01% | 3345 |
|
|
2016
Q1 | – | Sell |
-23,461
| Closed | -$1.01M | – | 4461 |
|
|
2015
Q4 | $1.01M | Buy |
23,461
+10,691
| +84% | +$452K | 0.01% | 1724 |
|
|
2015
Q3 | $479K | Buy |
+12,770
| New | +$453K | ﹤0.01% | 2345 |
|
|
2014
Q2 | – | Sell |
-13,318
| Closed | -$455K | – | 2928 |
|
|
2014
Q1 | $455K | Buy |
13,318
+485
| +4% | +$15K | 0.01% | 1656 |
|
|
2013
Q4 | $269K | Buy |
+12,833
| New | +$325K | ﹤0.01% | 1749 |
|
Other funds holding MYGN
VPC
Jane Street's MYGN Position: Q2 2026 in Review
Jane Street sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 1,202,531 shares — an estimated $5.41M sold.
Jane Street first reported a position in MYGN in Q4 2013 and held it in 30 quarters. The position peaked at $5.41M in Q1 2026. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.
- Jane Street reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
- Jane Street sold 1,202,531 Myriad Genetics shares in Q2 2026, an estimated $5.41M.
- Jane Street first reported a position in Myriad Genetics in Q4 2013 and held it in 30 quarters.
- Jane Street's Myriad Genetics position peaked at $5.41M in Q1 2026.
- 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.
Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.